Taille et prévisions du marché du traitement des infections des voies respiratoires MEA (2021-2031), part régionale, tendance et opportunités de croissance Couverture du rapport d’analyse : par médicament (antibiotiques, AINS, antitussifs, décongestionnants nasaux et autres), indication de la maladie (voies respiratoires supérieures et infection des voies respiratoires inférieures), voie d\'administration (orale et parentérale), groupe d\'âge (pédiatrique et adulte), canal de distribution (pharmacies hospitalières, pharmacies en ligne et pharmacies de détail) et pays

BMIRE00030044 | Pages: 201 | Pharmaceuticals | Mar 2024 | Type: Regional | Status: Published
La taille du marché du traitement des infections des voies respiratoires de la MEA devrait passer de 2,09 milliards de dollars américains en 2023 à 2,97 milliards de dollars américains d’ici 2031 ; on estime qu\'il enregistrera un TCAC de 4,50 % de 2023 à 2031. Augmentation de la demande de produits en vente libre pour traiter les infections respiratoires Opportunité de croissance du marché du traitement des infections des voies respiratoires MEA Un grand nombre de consommateurs recherchent des solutions accessibles et pratiques pour les symptômes respiratoires courants tels que comme la toux, la congestion et les maux de gorge. Cette approche permet aux individus qui ne souffrent pas de maladies potentiellement mortelles de surveiller et de contrôler étroitement leur santé. Cela permet également aux fabricants, aux pharmacies et aux prestataires de soins de santé de rendre leurs offres de produits plus adaptées aux applications en vente libre, d\'éduquer les consommateurs sur les pratiques d\'autosoins et d\'améliorer l\'accès aux options de traitement permettant de soulager divers symptômes. La popularité croissante des remèdes respiratoires en vente libre souligne l’importance de promouvoir la sensibilisation à la santé respiratoire, de favoriser les stratégies d’autogestion et un écosystème de soins de santé collaboratif. En tirant parti de la popularité croissante des produits respiratoires en vente libre, les acteurs du marché du traitement des infections des voies respiratoires dans la MEA peuvent renforcer l’engagement des patients, promouvoir des mesures de santé préventives et répondre aux besoins changeants de diverses populations en matière de soins de santé. Ainsi, la demande croissante de produits en vente libre pour gérer les infections respiratoires représente une opportunité importante pour le marché du traitement des infections des voies respiratoires MEA. Informations basées sur les médicaments En termes de médicaments, le segment des antibiotiques détenait la plus grande part de marché du traitement des infections des voies respiratoires MEA en 2023. Le même devrait enregistrer le TCAC le plus élevé au cours de la période 2023-2031. Les infections des voies respiratoires englobent une gamme de maladies, notamment la bronchite, la pneumonie et la sinusite, souvent causées par des agents pathogènes bactériens. Informations basées sur les indications de la maladie Sur la base des indications de la maladie, le segment des infections des voies respiratoires inférieures détenait une part de marché plus importante en 2023. Il est en outre prévu d\'enregistrer un TCAC plus élevé de 2023 à 2031. Les infections des voies respiratoires inférieures (IVRI) sont des infections qui affectent le poumons et bronches, généralement causés par des agents pathogènes bactériens, viraux ou fongiques, entre autres. Informations basées sur la voie d\'administration Par voie d\'administration, le segment oral détenait une part plus importante du marché du traitement des infections des voies respiratoires MEA ; le même segment devrait enregistrer un TCAC plus élevé au cours de la période 2023-2031. Des antibiotiques oraux tels que l\'amoxicilline, l\'azithromycine ou la doxycycline sont fréquemment prescrits pour lutter contre les agents pathogènes bactériens provoquant des infections des voies respiratoires. Informations basées sur le groupe d’âge En termes de groupe d’âge, le segment des adultes détenait une part plus importante du marché du traitement des infections des voies respiratoires MEA en 2023. Le segment de la pédiatrie devrait enregistrer un TCAC plus élevé au cours de la période 2023-2031. La forte prévalence des infections des voies respiratoires chez les enfants est un facteur clé qui nécessite des options de traitement efficaces. Informations basées sur le canal de distribution En termes de canal de distribution, le segment des pharmacies hospitalières devrait représenter une part de marché importante au cours de la période 2023-2031. Les pharmacies hospitalières constituent des éléments clés d’un système de santé ; ils jouent particulièrement un rôle essentiel dans la gestion des infections aiguës et graves des voies respiratoires, qui nécessitent l\'administration de médicaments par voie intraveineuse ou intramusculaire. Quelques-unes des principales sources primaires et secondaires mentionnées lors de la préparation du rapport sur le marché du traitement des infections des voies respiratoires de la MEA sont la Dubai Health Authority, la Saudi Initiative for Asthma et la Saudi Thoracic Society.
Table of Contents

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. MEA Respiratory Tract Infection Treatment Market Landscape

4.1 Overview

4.2 PEST Analysis

5. MEA Respiratory Tract Infection Treatment Market - Key Market Dynamics

5.1 MEA Respiratory Tract Infection Treatment Market - Key Market Dynamics

5.2 Key Market Drivers

5.2.1 Rising Cases of Respiratory Infections in Middle East

5.2.2 Increasing Awareness Related to Respiratory Tract Infections

5.3 Key Market Restraints

5.3.1 Lack of Research Focused on Respiratory Therapeutics

5.4 Key Market Opportunities

5.4.1 Surge in Demand for OTC Products to Treat Respiratory Infections

5.5 Future Trends

5.5.1 Advent of Antiviral Treatment for MERS

5.6 Impact of Drivers and Restraints:

6. MEA Respiratory Tract Infection Treatment Market Analysis

6.1 MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023-2031

7. MEA Respiratory Tract Infection Treatment Market Analysis - by Drugs

7.1 Antibiotics

7.1.1 Overview

7.1.2 Antibiotics: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

7.2 NSAIDs

7.2.1 Overview

7.2.2 NSAIDs: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

7.3 Cough Suppressants

7.3.1 Overview

7.3.2 Cough Suppressants: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

7.4 Nasal Decongestants

7.4.1 Overview

7.4.2 Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

8. MEA Respiratory Tract Infection Treatment Market Analysis - by Disease Indication

8.1 Lower Respiratory Tract Infection

8.1.1 Overview

8.1.2 Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

8.2 Upper Respiratory Tract Infection

8.2.1 Overview

8.2.2 Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

9. MEA Respiratory Tract Infection Treatment Market Analysis - by Route Of Administration

9.1 Oral

9.1.1 Overview

9.1.2 Oral: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

9.2 Parenteral

9.2.1 Overview

9.2.2 Parenteral: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

10. MEA Respiratory Tract Infection Treatment Market Analysis - by Age Group

10.1 Pediatrics

10.1.1 Overview

10.1.2 Pediatrics: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

10.2 Adults

10.2.1 Overview

10.2.2 Adults: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

11. MEA Respiratory Tract Infection Treatment Market Analysis - by Distribution Channel

11.1 Hospital Pharmacies

11.1.1 Overview

11.1.2 Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

11.2 Retail Pharmacies

11.2.1 Overview

11.2.2 Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

11.3 Online Pharmacies

11.3.1 Overview

11.3.2 Online Pharmacies: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

12. MEA Respiratory Tract Infection Treatment Market - Country Analysis

12.1 Middle East and Africa

12.1.1 MEA Respiratory Tract Infection Treatment Market Breakdown by Countries

12.1.2 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis - by Country

12.1.3 MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2030

12.1.3.1 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis - by Country

12.1.3.2 Saudi Arabia

12.1.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

12.1.3.3.1 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.3.2 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.3.4 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.3.5 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

12.1.3.4 South Africa

12.1.3.5 South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

12.1.3.5.1 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.5.2 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.5.3 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.5.4 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.5.5 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

12.1.3.6 UAE

12.1.3.7 UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

12.1.3.7.1 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.7.2 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.7.3 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.7.4 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.7.5 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

12.1.3.8 Rest of MEA

12.1.3.9 REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

12.1.3.9.1 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.9.2 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.9.3 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.9.4 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.9.5 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

13. Company Profiles

13.1 Abbott Laboratories

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Teva Pharmaceutical Industries Ltd

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Sanofi SA

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Boehringer Ingelheim International GmbH

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 AstraZeneca Plc

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Alembic Pharmaceuticals Ltd

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 GSK Plc

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Novartis AG

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 F. Hoffmann-La Roche Ltd

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Gulf Pharmaceutical Industries Co

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

List of TablesTable 1. MEA Respiratory Tract Infection Treatment Market Segmentation

Table 2. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs

Table 3. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication

Table 4. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration

Table 5. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group

Table 6. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel

Table 7. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Country

Table 8. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs

Table 9. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication

Table 10. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration

Table 11. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group

Table 12. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel

Table 13. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs

Table 14. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication

Table 15. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration

Table 16. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group

Table 17. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel

Table 18. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs

Table 19. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication

Table 20. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration

Table 21. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group

Table 22. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel

Table 23. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs

Table 24. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication

Table 25. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration

Table 26. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group

Table 27. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel

Table 28. Glossary of Terms, MEA Respiratory Tract Infection Treatment Market

List of Figures

Figure 1. MEA Respiratory Tract Infection Treatment Market Segmentation, by Country

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023-2031

Figure 5. MEA Respiratory Tract Infection Treatment Market Share (%) - by Drugs, 2023 and 2031

Figure 6. Antibiotics: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 7. NSAIDs: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 8. Cough Suppressants: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 9. Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 10. MEA Respiratory Tract Infection Treatment Market Share (%) - by Disease Indication, 2023 and 2031

Figure 11. Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 12. Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 13. MEA Respiratory Tract Infection Treatment Market Share (%) - by Route Of Administration, 2023 and 2031

Figure 14. Oral: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 15. Parenteral: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 16. MEA Respiratory Tract Infection Treatment Market Share (%) - by Age Group, 2023 and 2031

Figure 17. Pediatrics: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 18. Adults: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 19. MEA Respiratory Tract Infection Treatment Market Share (%) - by Distribution Channel, 2023 and 2031

Figure 20. Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 21. Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 22. Online Pharmacies: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)

Figure 23. MEA Respiratory Tract Infection Treatment Market Breakdown by Key Countries, 2023 and 2031 (%)

Figure 24. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2030(US$ Million)

Figure 25. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

Figure 26. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

Figure 27. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

Figure 28. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

The List of Companies - MEA Respiratory Tract Infection Treatment Market

  • Abbott Laboratories

  • AstraZeneca plc

  • Alembic Pharmaceuticals Ltd.

  • Boehringer Ingelheim International GmbH

  • GlaxoSmithKline plc

  • Teva Pharmaceutical Industries Ltd

  • Novartis AG

  • F. Hoffmann-La Roche AG

  • Sanofi S.A.

  • Orion Corporation

  • Julphar
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the MEA Respiratory Tract Infection Treatment Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the MEA Respiratory Tract Infection Treatment Market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the MEA Respiratory Tract Infection Treatment Market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
  • Report Code
    Full Name
    Country Name
    Email Id
    Phone Number
    Job Title
    Company
    Requirement

    Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


    Purchase Options
    Single User License
    $3550
    $2840
    Site License
    $4550
    $3640
    Enterprise License
    $5550
    $4440